{
    "nct_id": "NCT05194072",
    "official_title": "A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors",
    "inclusion_criteria": "For Parts A, B, and C:\n\n* Participants must have one of the following histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor types:\n\n  * High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer\n  * HER2-negative, HR positive breast cancer\n  * Triple-negative breast cancer (TNBC)\n  * Endometrial carcinoma\n  * Non-small cell lung cancer (Squamous cell carcinoma [SqCC], Adenocarcinoma [AC])\n  * Cholangiocarcinoma or gallbladder carcinoma\n  * Adenoid cystic carcinoma (ACC) For Part D: Participants must have histologically or cytologically confirmed locally advanced unresectable or metastatic TNBC.\n\nFor Part E:\n\n* Cohort E1: Participants must have histologically or cytologically confirmed locally advanced unresectable or metastatic TNBC and must have CPS≥10 by local testing\n* Cohort E2: Participants must have histologically or cytologically confirmed locally advanced unresectable or metastatic TNBC and must have CPS<10 by local testing\n* Cohort E3: Participants must have triple negative breast cancer with residual disease following neoadjuvant therapy and definitive surgery\n\n  * Parts A and B: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, and, in the judgement of the investigator, should have no appropriate SOC therapeutic option\n  * Part C: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies.\n  * Part D and E1/E2: Participants must have had no prior treatment for locally advanced unresectable or metastatic TNBC\n  * Part E3: Participants must have completed at least 6 cycles of neoadjuvant therapy for locally advanced unresectable or metastatic TNBC\n  * Tumor tissue is required for enrollment.\n  * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n  * Measurable disease per RECIST version 1.1 at baseline (not applicable for E3 participants).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of another malignancy within 3 years before the first dose of study drug. Any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.\n* Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:\n\n  * are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment\n  * have no new or enlarging brain metastases\n  * and are off corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study treatment.\n* Carcinomatous meningitis\n* Previous receipt of an MMAE-containing agent or an agent targeting B7-H4\n* Pre-existing neuropathy ≥ Grade 2 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0\n* Corneal disease or injury requiring treatment or active monitoring",
    "miscellaneous_criteria": ""
}